🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

An International Health Concern

Cases of gonorrhoea are increasing worldwide, with figures suggesting more than 82 million instances each year. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs currently available.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, also received approval in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a major breakthrough in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Outcomes and Global Access

As per results published in a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which uses two antibiotics. The research involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to make available and distribute the drug in numerous regions with limited resources.

Medical professionals treating patients have expressed optimism. The availability of a one-pill regimen such as this is seen as a "game-changer" for public health efforts. This is considered essential to reduce the burden of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.